Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models

Neuropharmacology. 2015 Dec:99:187-95. doi: 10.1016/j.neuropharm.2015.07.014. Epub 2015 Jul 15.

Abstract

Stopping the ischemic cascade by targeting its components is a potential strategy for acute ischemic stroke treatment. During ischemia and especially over reperfusion, oxidative stress plays a major role in causing neuronal cell death. Melatonin has been previously reported to provide neuroprotective effects in in vivo models of stroke by a mechanism that implicates melatonin receptors. In this context, this study was planned to test the potential neuroprotective effects of the novel melatonin MT1/MT2 receptor agonist, Neu-P11, against brain ischemia in in vitro and in vivo models, and to elucidate its underlying mechanism of action. Neu-P11 proved to be a good antioxidant, to protect against glutamate-induced excitotoxicity and oxygen and glucose deprivation in hippocampal slices, and to reduce infarct volume in an in vivo stroke model. Regarding its mechanism of action, the protective effect of Neu-P11 was reverted by luzindole (melatonin receptor antagonist), AG490 (JAK2 inhibitor), LY294002 (PI3/AKT inhibitor) and PD98059 (MEK/ERK1/2 inhibitor). In conclusion, Neu-P11 affords neuroprotection against brain ischemia in in vitro and in vivo models by activating a pro-survival signaling pathway that involves melatonin receptors, JAK/STAT, PI3K/Akt and MEK/ERK1/2.

Keywords: Brain ischemia; In vitro; In vivo; JAK2/AKT/ERK1/2; Neu-P11; Neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Brain / drug effects
  • Brain / pathology
  • Brain / physiopathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Brain Ischemia / physiopathology
  • Cell Hypoxia / drug effects
  • Cell Hypoxia / physiology
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Glucose / deficiency
  • Humans
  • Indoles / pharmacology*
  • Male
  • Melatonin / analogs & derivatives
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology*
  • Pyrans / pharmacology*
  • Random Allocation
  • Rats, Sprague-Dawley
  • Receptors, Melatonin / agonists
  • Receptors, Melatonin / antagonists & inhibitors
  • Receptors, Melatonin / metabolism
  • Tissue Culture Techniques

Substances

  • Antioxidants
  • Indoles
  • Neuroprotective Agents
  • Pyrans
  • Receptors, Melatonin
  • Glucose
  • Melatonin
  • N-(2-(5-methoxy-indol-3-yl)-ethyl)-4-oxo-4H-pyran-2-carboxamide